<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-10-02-2026-shutterstock_2427838693-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-10-02-2026-shutterstock_2427838693-430x241.jpg"/>
                                    
                                    <figcaption>Through this arrangement, Takeda will gain access to NeuralPLexer, Iambic’s model for predicting protein-ligand complexes. Credit: Veroniksha / Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Takeda has entered a multi-year partnership to utilise Iambic’s AI drug discovery models for advancing small molecule programmes, in a deal that could exceed $1.7bn.</p>



<p>The Takeda-Iambic AI drug discovery collaboration will initially focus on projects in oncology and gastrointestinal therapeutic area, as well as that of inflammation.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>NPVM: Bicycle Therapeutics Plc's BT-1718 </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>NPVM: Sanofi's Tusamitamab ravtansine </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>Through this arrangement, Takeda will gain access to Iambic’s model for predicting protein-ligand complexes, NeuralPLexer.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>The partnership aims to advance several high-priority small molecule programmes using Iambic’s AI models and automated wet lab capabilities.</p>



<p>Under the deal, Iambic will be eligible for upfront payments, research cost contributions, technology access fees, success-based payments potentially exceeding $1.7bn, plus royalties on net sales of any resulting products.</p>



<p>Iambic co-founder and CEO Tom Miller said: “Our collaboration with Takeda is a powerful opportunity to apply our AI-driven discovery and development platform, and we are excited to partner with their team to quickly advance new and better drug candidates.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>“This collaboration further validates our industry-leading technology and highlights both the breadth of our discovery capabilities and the scale at which we can operate.”</p>



<p>Takeda chief scientific officer and research head Chris Arendt said: “We are excited to be able access Iambic’s proprietary computational platform while we work with their team to develop small molecule therapeutics with the potential to address critical unmet patient needs.</p><div id="slot-two"></div>



<p>“At Takeda, our focus is on accelerating the development of impactful new medicines by leveraging cutting-edge science, including the latest advances in artificial intelligence. Iambic’s small molecule platform aligns with this ambition and offers the potential to de-risk candidate selection, improve the probability of success, and more quickly advance select programmes from early project start to IND [investigational new drug].”</p>



<p>Last month, Takeda announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the latter’s Enhanze drug delivery technology.</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>

4502

<p>Takeda has formed a multi-year partnership with Iambic to utilize its AI drug discovery models for small molecule programs, in a deal potentially worth over $1.7 billion. The collaboration will focus on oncology, gastrointestinal, and inflammation projects, granting Takeda access to Iambic's NeuralPLexer model for predicting protein-ligand complexes. Iambic will receive upfront payments, research contributions, technology fees, and royalties on resulting products. Both companies aim to accelerate the development of new therapeutics using advanced AI technology.</p>

Takeda and Iambic announce $1.7bn deal to advance small molecule programmes